Filling a Vital Gap in the Treatment of Coronary Artery Disease
Inflammation is major driver of heart attacks for patients with coronary artery disease (CAD). Using a new therapeutic approach, we are addressing the problem in a highly specific manner to maximize benefit to patients while also minimizing the risks.
Coronary Artery Disease (CAD) is the #1 cause of death worldwide.
CAD is the leading cause of death worldwide. It is a condition characterized by the buildup of plaque in the arteries that supply blood to the heart muscle (a condition called atherosclerosis). This build-up causes inflammation, which often goes untreated, and ultimately leads to an acute coronary syndrome (ACS) event such as a heart attack or unstable angina.
Abcentra’s innovative solution is a highly specific approach to quell coronary inflammation.
When choosing an approach to treat coronary inflammation – specificity matters.
Doctors need a targeted approach that provides the ability to intervene with precision, which has promise to maximize the benefit to patients while minimizing the risks.
Abcentra’s core technology allows for targeting of oxidized low-density lipoprotein (OxLDL) – an inflammatory mediator with no known role in the health and a well-established role in CAD.
Our lead therapeutic candidate, orticumab, is a clinical-stage, first-in-class monoclonal antibody therapy against a oxLDL.
latest news & insights
Keep up with our work, find new resources, and stay on top of important news regarding the future of treatment for coronary artery disease.
Join our team at an event near you.
You can find our team at cardiovascular events around the globe.
Attend some of these events and use the form on our contact page to schedule a meeting.
